Abstract
LIVE oral poliovirus vaccine is responsible for the almost complete elimination of paralytic polio-myelitis.<sup>1,2</sup>Henderson et al's<sup>1</sup>data reveal the risk of paralytic poliomyelitis from live oral vaccine to vary according to the vaccine type and age of the recipient. The rate for type I vaccine is 0.17 per million doses administered; for type II, 0.02; and for type III, 0.4. In the older age group, especially for type III vaccine, the rate is 0.64 per million doses given. Dissemination of poliovirus occurs in close contacts following exposure to a recent vaccine recipient; however, cases of paralytic poliomyelitis acquired in such a manner have been exceedingly rare.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
